121 related articles for article (PubMed ID: 38042310)
21. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
Lu Y; Liu Y; Lan J; Chan YT; Feng Z; Huang L; Wang N; Pan W; Feng Y
J Adv Res; 2023 Sep; 51():181-196. PubMed ID: 36351536
[TBL] [Abstract][Full Text] [Related]
22. Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells.
Jeng LB; Velmurugan BK; Hsu HH; Wen SY; Shen CY; Lin CH; Lin YM; Chen RJ; Kuo WW; Huang CY
Environ Toxicol; 2018 Feb; 33(2):234-247. PubMed ID: 29134746
[TBL] [Abstract][Full Text] [Related]
23. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway.
Huang GM; Jiang QH; Cai C; Qu M; Shen W
Cancer Lett; 2015 Mar; 358(2):180-190. PubMed ID: 25528629
[TBL] [Abstract][Full Text] [Related]
24. Gene Network Analysis of Glucose Linked Signaling Pathways and Their Role in Human Hepatocellular Carcinoma Cell Growth and Survival in HuH7 and HepG2 Cell Lines.
Berger E; Vega N; Weiss-Gayet M; Géloën A
Biomed Res Int; 2015; 2015():821761. PubMed ID: 26380295
[TBL] [Abstract][Full Text] [Related]
25. E
Chang-Lee SN; Hsu HH; Shibu MA; Ho TJ; Tsai CH; Chen MC; Tu CC; Viswanadha VP; Kuo WW; Huang CY
Pathol Oncol Res; 2017 Jul; 23(3):477-485. PubMed ID: 27757837
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation.
Shah YM; Morimura K; Yang Q; Tanabe T; Takagi M; Gonzalez FJ
Mol Cell Biol; 2007 Jun; 27(12):4238-47. PubMed ID: 17438130
[TBL] [Abstract][Full Text] [Related]
27. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
28. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
30. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
31. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.
Zhang N; Chu ES; Zhang J; Li X; Liang Q; Chen J; Chen M; Teoh N; Farrell G; Sung JJ; Yu J
Oncotarget; 2014 Sep; 5(18):8330-40. PubMed ID: 25327562
[TBL] [Abstract][Full Text] [Related]
33. Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Feng T; Wu T; Zhang Y; Zhou L; Liu S; Li L; Li M; Hu E; Wang Q; Fu X; Zhan L; Xie Z; Xie W; Huang X; Shang X; Yu G
Front Oncol; 2022; 12():912694. PubMed ID: 35957896
[TBL] [Abstract][Full Text] [Related]
34. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
35. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
36. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis.
Li H; Chen Z; Zhang Y; Yuan P; Liu J; Ding L; Ye Q
Cancer Lett; 2021 Oct; 519():161-171. PubMed ID: 34303763
[TBL] [Abstract][Full Text] [Related]
37. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Liu J; Cui X; Qu L; Hua L; Wu M; Shen Z; Lu C; Ni R
Exp Mol Pathol; 2016 Aug; 101(1):58-65. PubMed ID: 27302463
[TBL] [Abstract][Full Text] [Related]
39. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
40. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
